MAGNET

Magnet Biomedicine is a biotechnology company pioneering the rational discovery of "TrueGlues," a novel class of molecular glues designed to induce or stabilize protein-protein interactions. Unlike traditional molecular glues that primarily focus on protein degradation, Magnet's approach aims to harness the full functional potential of the proteome by targeting diverse protein-protein interactions across various therapeutic areas. The company's proprietary TrueGlue platform integrates structural biology, high-throughput screening, and computational chemistry to identify and optimize these small molecules. Magnet is currently advancing a pipeline of programs focused on oncology, immunology, and other diseases with high unmet medical needs. By enabling the drugging of previously inaccessible targets, the company seeks to transform the landscape of small molecule therapeutics.